PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-36.86%
Negative ROE while Healthcare median is 0.74%. Seth Klarman would investigate if capital structure or industry issues are at play.
80.34%
ROA of 80.34% while Healthcare median is zero. Peter Lynch would see if minimal profitability can widen over time.
395.15%
ROCE exceeding 1.5x Healthcare median of 1.18%. Joel Greenblatt would look for a high return on incremental capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.